Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 immunoPET CD8 imaging in large B-cell lymphoma before and after CD19 CAR T-cell therapy
2025-520560-18-00Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 89Zr-glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University Medical Center Groningen. Started Jan 2025; status: completed.
02
Drugs
89Zr-glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2025-520560-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520560-18-00.